HP R&D decreased by 1.5% to $392.00M in Q4 2025 compared to the prior quarter. Year-over-year, this metric declined by 1.3%, from $397.00M to $392.00M. Over 4 years (FY 2021 to FY 2025), R&D shows a downward trend with a -3.5% CAGR.
Higher spending signals a commitment to innovation and future product launches, whereas significant cuts may indicate a shift toward short-term profitability.
Research and development expenses represent the costs incurred to discover new products, improve existing technologies,...
Highly comparable across pharmaceutical and medical device peers, where R&D intensity is a key metric for long-term valuation.
research_and_development| Q1 '21 | Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $514.00M | $477.00M | $386.00M | $478.00M | $425.00M | $368.00M | $382.00M | $403.00M | $410.00M | $354.00M | $411.00M | $399.00M | $436.00M | $413.00M | $392.00M | $397.00M | $401.00M | $406.00M | $398.00M | $392.00M |
| QoQ Change | — | -7.2% | -19.1% | +23.8% | -11.1% | -13.4% | +3.8% | +5.5% | +1.7% | -13.7% | +16.1% | -2.9% | +9.3% | -5.3% | -5.1% | +1.3% | +1.0% | +1.2% | -2.0% | -1.5% |
| YoY Change | — | — | — | — | -17.3% | -22.9% | -1.0% | -15.7% | -3.5% | -3.8% | +7.6% | -1.0% | +6.3% | +16.7% | -4.6% | -0.5% | -8.0% | -1.7% | +1.5% | -1.3% |